A list of commonly used measurement tools for psoriasis management and clinical trials.
General
A simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages to measure disease severity and quality of life.
To express the severity of psoriasis by measuring redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
PGA: Physician's Global Assessment
Physician's assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic, plaque psoriasis.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version as well as The Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis
IPC does not endorse or accept any responsibility for the content of external websites.
congress coverage EADV 2019 Read the psoriasis highlights from the EADV 2019 congress learn more
Latest news Commentary: Dermatologists and SARS - CoV - 2: the impact of the pandemic on daily practiceJuly 22, 2020Paolo Gisondi et al., summarize issues faced by many dermatologists during the unprecedented lockdown period in Spring 2020 due to the COVID-19 pandemic. Issues like the sudden cancellation of face-to-face consultations, and the mandatory introduction of telemedicine (after months of a rather optional exercise with this type of caregiving), needed an entrepreneurial approach to manage. Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque PsoriasisJuly 20, 2020Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study. OASIS-2 is a multicenter randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mirikizumab to placebo and Cosentyx in patients with moderate to severe plaque psoriasis. Pathogenesis of PsoriasisJuly 14, 2020Dr. Stingl discusses differences in the pathogenesis of plaque psoriasis and pustular psoriasis. Spoiler alert: it's the neutrophils. PsoProtectMe now available in multiple languagesJuly 09, 2020PsoProtectMe now available in multiple languages More News